Treatment Options for Urinary Retention

Initial Assessment and Management

The American Urological Association recommends confirming urinary retention through bladder scanning or straight catheterization to quantify residual volume 1
Immediate bladder decompression via urethral catheterization is recommended for relief of acute urinary retention, with consideration of silver alloy-coated urinary catheters to reduce urinary tract infection risk 1
If blood is present at the urethral meatus after pelvic trauma, retrograde urethrography should be performed before attempting catheterization to rule out urethral injury 1

Alpha blockers, such as tamsulosin or alfuzosin, should be administered prior to attempting catheter removal to improve chances of successful voiding trial, with reported success rates of 60% versus 39% for placebo with alfuzosin, and 47% versus 29% for placebo with tamsulosin 1, 2
For BPH-related retention, combination therapy with alpha blockers and 5-alpha reductase inhibitors, like finasteride, may be considered for preventing future episodes of retention in men with large prostates 1

Transurethral resection of the prostate (TURP) is the benchmark surgical treatment for BPH-related urinary retention 1
For urethral stricture causing retention, options include urethral dilation, direct visual internal urethrotomy, or urethroplasty 1
Sphincterotomy may be offered to facilitate emptying in male patients with neurogenic lower urinary tract dysfunction (NLUTD), but patients must be counseled about the high risk of failure or potential need for additional treatment 3

For BPH-related retention, initial management with alpha blockers followed by a voiding trial is recommended, with surgical intervention if the voiding trial fails 1, 2
For neurogenic bladder, intermittent catheterization is generally recommended rather than indwelling catheters, and onabotulinumtoxinA may be offered to improve bladder storage parameters and decrease episodes of incontinence 1, 2, 3
Patients with neurogenic bladder must be counseled about the risk of urinary retention after botulinum toxin therapy, with a reported risk of 20.49% for onabotulinumtoxinA versus 3.67% for placebo 3

Indwelling catheters should be removed as soon as medically possible, ideally within 24-48 hours, to minimize infection risk 1
Patients who successfully void after catheter removal should be informed that they remain at increased risk for recurrent urinary retention 2
Regular follow-up is essential for patients with chronic retention requiring long-term catheterization to assess for complications such as UTI, bladder stones, and renal function deterioration 1

Delaying surgical intervention in patients with refractory retention can lead to bladder decompensation and chronic retention 1
Prolonged use of indwelling catheters increases the risk of urinary tract infections and should be avoided when possible 2
Prostatic stents may be considered for high-risk patients who cannot undergo other treatments, but are associated with significant complications including encrustation, infection, and chronic pain 1